<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shan C</submitter><funding>HHS | National Institutes of Health</funding><funding>NCATS NIH HHS</funding><funding>NIAID NIH HHS</funding><pagination>e01002-18</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6189489</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>92(21)</volume><pubmed_abstract>Dengue virus (DENV) is the most prevalent mosquito-transmitted viral pathogen in humans. The recently licensed dengue vaccine has major weaknesses. Therefore, there is an urgent need to develop improved dengue vaccines. Here, we report a virion assembly-defective DENV as a vaccine platform. DENV containing an amino acid deletion (K188) in nonstructural protein 2A (NS2A) is fully competent in viral RNA replication but is completely defective in virion assembly. When &lt;i>trans&lt;/i>-complemented with wild-type NS2A protein, the virion assembly defect could be rescued, generating pseudoinfectious virus (PIV&lt;sub>NS2A&lt;/sub>) that could initiate single-round infection. The &lt;i>trans&lt;/i>-complementation efficiency could be significantly improved through selection for adaptive mutations, leading to hi</pubmed_abstract><journal>Journal of virology</journal><pubmed_title>Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach.</pubmed_title><pmcid>PMC6189489</pmcid><funding_grant_id>AI127744</funding_grant_id><funding_grant_id>R01 AI127744</funding_grant_id><funding_grant_id>UL1 TR001439</funding_grant_id><pubmed_authors>Zou J</pubmed_authors><pubmed_authors>Zust R</pubmed_authors><pubmed_authors>Xie X</pubmed_authors><pubmed_authors>Fink K</pubmed_authors><pubmed_authors>Shi PY</pubmed_authors><pubmed_authors>Ambrose R</pubmed_authors><pubmed_authors>Shan C</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Mackenzie J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach.</name><description>Dengue virus (DENV) is the most prevalent mosquito-transmitted viral pathogen in humans. The recently licensed dengue vaccine has major weaknesses. Therefore, there is an urgent need to develop improved dengue vaccines. Here, we report a virion assembly-defective DENV as a vaccine platform. DENV containing an amino acid deletion (K188) in nonstructural protein 2A (NS2A) is fully competent in viral RNA replication but is completely defective in virion assembly. When &lt;i>trans&lt;/i>-complemented with wild-type NS2A protein, the virion assembly defect could be rescued, generating pseudoinfectious virus (PIV&lt;sub>NS2A&lt;/sub>) that could initiate single-round infection. The &lt;i>trans&lt;/i>-complementation efficiency could be significantly improved through selection for adaptive mutations, leading to hi</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Nov</publication><modification>2025-04-05T00:11:30.442Z</modification><creation>2019-06-06T20:18:21Z</creation></dates><accession>S-EPMC6189489</accession><cross_references><pubmed>30111567</pubmed><doi>10.1128/JVI.01002-18</doi><doi>10.1128/jvi.01002-18</doi></cross_references></HashMap>